论文部分内容阅读
诺华公司Rasitrio近日获欧盟批准。本品为由阿利克仑(aliskiren)、氨氯地平与氢氯噻嗪组合而成的复方降压药,曾获准作为联合三种药物治疗后血压得到控制的患者的替代用药。
Novartis Rasitrio recently approved by the EU. This product is a combination of aliskiren (aliskiren), amlodipine and hydrochlorothiazide combination of antihypertensive drugs, has been approved as a combination of three drugs to control the blood pressure in patients under the control of alternative medicine.